Exenatide

Exenatide is a 39-amino-acid GLP-1 receptor agonist, a synthetic version of exendin-4 found in Gila monster saliva. It was the first GLP-1 receptor agonist approved by the FDA, as Byetta and later Bydureon, for type 2 diabetes.

Last reviewed 2026-10-25 by the PeptideWiki editorial team. Editorial policy.

Overview

Exenatide is the synthetic form of exendin-4, a peptide isolated from the saliva of the Gila monster (Heloderma suspectum), a venomous lizard of the southwestern United States and Mexico. Exendin-4 shares about half of its sequence with human GLP-1 and activates the GLP-1 receptor, but it resists degradation by the enzyme dipeptidyl peptidase-4, which inactivates native GLP-1 within minutes. This discovery made exendin-4 the first practical template for an incretin-based drug.

Exenatide was developed by Amylin Pharmaceuticals with Eli Lilly and approved by the FDA as Byetta, a twice-daily injection, for type 2 diabetes. An extended-release formulation using biodegradable microspheres was later approved as Bydureon for once-weekly use. Exenatide is a landmark compound in peptide drug history, and exendin fragments remain important research tools, including the antagonist exendin(9-39). Its development also showed how natural peptides from animal venoms can serve as drug templates.

Structure

Exenatide is a linear 39-residue peptide with the sequence His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ and a C-terminal amide. Glycine at position 2, in place of the alanine of GLP-1, confers resistance to dipeptidyl peptidase-4. The C-terminal nine-residue extension, sometimes called the Trp-cage, is not present in GLP-1 and contributes to its folded structure. The sequence contains methionine and tryptophan, both prone to oxidation. Exenatide is identical in sequence to natural exendin-4.

Mechanism

Exenatide is a full agonist of the GLP-1 receptor. It enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying and reduces food intake. Because insulin release depends on glucose levels, the intrinsic risk of hypoglycemia is low when exenatide is used without other agents that cause hypoglycemia.

Resistance to dipeptidyl peptidase-4 extends its activity compared with native GLP-1, but exenatide is still cleared relatively quickly, mainly by the kidneys, which is why the original formulation required twice-daily injection. The extended-release formulation achieves weekly dosing through slow release from microspheres rather than molecular modification.

Research

Discovery of exendin-4

Exendin-4 was isolated and characterized in the early 1990s by researchers studying peptides in Gila monster venom, building on earlier discovery of the related exendin-3 in another Heloderma species. They found it acted on receptors in pancreatic tissue, and it was later shown to be a potent GLP-1 receptor agonist resistant to enzymatic breakdown. The truncated peptide exendin(9-39) was found to block the receptor and became a standard GLP-1 receptor antagonist in research.

Type 2 diabetes trials

Phase 3 trials of twice-daily exenatide as an add-on to metformin, sulfonylureas or both showed improvements in HbA1c and modest weight loss compared with placebo. These results supported FDA approval of Byetta in 2005. Later trials of once-weekly extended-release exenatide, such as the DURATION program, compared it with twice-daily exenatide and other agents, supporting approval of Bydureon. Its twice-daily regimen reflected relatively rapid renal clearance.

Cardiovascular outcomes: EXSCEL

EXSCEL was a large randomized trial of once-weekly exenatide in people with type 2 diabetes, with or without prior cardiovascular disease, published in 2017. It met its primary safety objective of noninferiority for major adverse cardiovascular events compared with placebo, but the reduction in events did not reach statistical significance for superiority. EXSCEL is often compared with outcome trials of other GLP-1 receptor agonists.

Neurological and other research

Exenatide has been studied in Parkinson's disease, based on preclinical evidence of neuroprotective effects in animal models. Earlier smaller trials reported encouraging signals, but a larger phase 3 trial did not show a benefit on disease progression. Exenatide has also been studied in conditions such as hypoglycemia after bariatric surgery and in obesity. These uses remain investigational. Exenatide and exendin(9-39) also remain widely used tools in laboratory studies of GLP-1 receptor biology.

Regulatory status

Exenatide is FDA-approved for type 2 diabetes as Byetta (twice-daily injection) and Bydureon (extended-release formulations); availability of individual products has changed over time, so check current listings. Indications are defined by current labeling. It is also approved in other countries. For sport, check the current WADA Prohibited List.

Status changes often. See the regulatory tracker for dated updates.

Quality and identity testing

A certificate of analysis should confirm identity by mass spectrometry against the expected mass shown on this page and report reverse-phase HPLC purity with the chromatogram. Methionine at position 14 readily oxidizes (+16 Da) and tryptophan can also oxidize, so oxidized variants should be quantified. Deamidation of Asn28 or Gln13 (+1 Da), C-terminal acid variants (+1 Da) and deletion sequences, including truncations at the proline-rich C-terminus, are other common impurities. Aggregation is possible at high concentrations. The counter-ion, typically acetate, and net peptide content should be stated.

Open Exenatide in the sequence analyzer to see the expected [M+H]⁺ and multiply charged ions for an MS identity check (set the N-acetyl, amide and disulfide options to match).

For a walkthrough of each section of a certificate, see how to read a COA.

Storage and stability

Store lyophilized exenatide sealed at -20 °C or colder, protected from light and moisture, and allow vials to reach room temperature before opening. The methionine and tryptophan residues make it sensitive to oxidation, so exposure to air and light should be minimized and solutions should be prepared in degassed buffer where practical. For lab use, keep solutions refrigerated for short-term work, aliquot for longer storage at -20 °C or below, and avoid repeated freeze-thaw cycles. Approved products have their own labeled storage requirements.

Download the Exenatide data sheet (PDF): sequence, masses, expected MS ions and handling on one printable page.

Latest research

Frequently asked questions

Related compounds

• Liraglutide

  Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist with a fatty acid side chain. It is FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).

• Semaglutide

  Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

• Pramlintide

  Pramlintide is a synthetic analogue of the pancreatic hormone amylin, modified with three proline substitutions to prevent aggregation. It is FDA-approved as Symlin for use with mealtime insulin in type 1 and type 2 diabetes.

• Tirzepatide

  Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors. It is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

References

1. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992. Find on PubMed
2. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017. Find on PubMed
3. PubMed: all indexed literature on Exenatide
4. ClinicalTrials.gov: registered studies mentioning Exenatide